1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6AC7595A3F4A47CA20025899100390EBF
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/case-study-how-argenx-broke-into-captive-market-to-begin-dislodging-entrenched-market-leader?opendocument
18
19opendocument
2018.207.129.175
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Product Launch » Product Launch Excellence

Case Study: How argenx Broke into a Captive Market to Begin Dislodging an Entrenched Market Leader

ID: PSM-388


Features:

67 Info Graphics

29 Data Graphics

360+ Metrics

7 Narratives


Pages: 110


Published: 2023


Delivery Format: Shipped


 

License Options:


Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
When drug manufacturer argenx entered the generalized Myasthenia Gravis (gMG) market in 2022 with the launch of its first product VYVGART, rival manufacturer Alexion had long since established a leading market position with its rare disease franchise of Soliris and Ultomiris.

With a new method-of-action treatment, however, VYVGART was just the “tip of the spear” for argenx’s own rare disease franchise, which features up to 16 indications in development. The stakes were thus very high for VYVGART's launch.

A case study of argenx reveals many valuable market-lessons, including how it actively engaged with external partnerships; secured early funding; used value-based contracting and competitive pricing strategies; and extended patient education, access and support levels established by Soliris / Ultomiris to break into the captive market.

This Best Practices, LLC case study utilizes an eight-point framework to examine VYVGART’s development, launch, and market-entry strategies and execution. The study also examines a host of diverse operating factors from clinical trial design, partnerships, and financing to market access, patient and commercial strategies.

Industries Profiled:
Biotech; Pharmaceutical


Companies Profiled:
argenx; Alexion Pharmaceuticals; AstraZeneca

Study Snapshot

Best Practices, LLC conducted extensive secondary research utilizing an eight-point framework to examine VYVGART’s development, launch, and market entry strategies and execution.

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • Winning Formula: VYVGART matched the market leader on patient support, presented higher efficacy data, and offered annual treatment pricing 51% below the leader.
  • Value-Based Contracts: VYVGART communicated its openness to value-based contracts, which won payer appreciation.
  • Partnerships: Argenx used multiple partnerships to extend its development expertise, financial resources, technology, academic research, and global reach.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Executive Summary - Key Insights & Research Findings Pg. 3-5
II.
argenx conceives gMG Market-Entry with VYVGART As A First Step in Franchise BuildingPg. 6-13
III.
argenx Actively Engaged With External Partnerships to Develop and Commercialize VYVGARTPg. 14-28
IV.
Securing Investment for argenx growth and VYVGART CommercializationPg. 29-39
V.
argenx Uses Competitive Pricing Strategies to Compete with Other Drugs already treating gMGPg. 40-50
VI.
VYVGART Entered the gMG Market Matching and Extending the Patient Education, Access and Support Levels Established by SOLIRIS / ULTOMIRISPg. 51-64
VII.
VYVGART’s Global Market Access StrategiesPg. 65-69
VIII.
VYVGART Staffing Analysis: Examining the talent and resources to compete in the gMG marketPg. 70-77
IX.
Competitor Analysis: How Alexion Started the Predecessor Rare Disease Franchise Which VYVGART Would ChallengePg. 78-85
X.
Competitor Analysis: Patient Education and Support Become the Platform to Support SOLIRIS Growth and Adherence in Rare DiseasePg. 86-99
XI.
ULTOMIRIS – Successor to SOLIRIS – Was Introduced To Protect and Extend Alexion / AstraZeneca's Rare Disease FranchisePg. 100-109
XII.
About Best Practices, LLCPg. 110